Treatment of Indolent Systemic Mastocytosis With PA101
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized, placebo- and active-controlled, 2-period crossover, 2 cohort study in
adult patients with indolent systemic mastocytosis (ISM).
The purpose of the study is to determine the efficacy and safety profile of PA101 delivered
via eFlow high efficiency nebulizer in patients with ISM who are symptomatic despite using
standard treatments.